Please use this identifier to cite or link to this item:
Title: Assessing the impact of FDG-PET in the management of anal cancer.
Austin Authors: Nguyen, Brandon T;Joon, Daryl Lim;Khoo, Vincent;Quong, George;Chao, Michael ;Wada, Morikatsu ;Joon, Michael Lim;See, Andrew;Feigen, Malcolm;Rykers, Kym;Kai, Cynleen;Zupan, Eddy;Scott, Andrew M 
Affiliation: Radiation Oncology Centre, Austin Health, Victoria, Australia
Issue Date: 29-Apr-2008
Publication information: Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology 2008; 87(3): 376-82
Abstract: To assess the utility of FDG-PET in anal cancer for staging and impact on radiotherapy planning (RTP), response and detection of recurrent disease.Fifty histopathological anal cancer patients were reviewed between 1996 and 2006. The median age was 58 years (range 36-85) with 19 males:31females. Clinical assessment with CT was compared to PET. Impact on management, disease response, recurrence and metastases was evaluated.The non-PET staging was Stage I(8), Stage II(18), Stage III(22), and Stage IV(2)s. The primary was strongly FDG avid in 98% with non-excised tumors compared to CT (58%). PET upstaged 17% with unsuspected pelvic/inguinal nodal disease. Pre-treatment PET identified 11 additional by involved nodal groups in 48 patients causing RTP amendments in 19%. Post-treatment PETs at median 17 weeks (range 9-28) showed complete responses in 20 (80%) and 5 (20%) partial responses (PR). PRs were biopsy positive in 2 and negative in 3. Fifteen had follow-up scans of which all nine PETs detected recurrences were pathologically confirmed.Anal cancer is FDG-PET avid. PET upstages 17% and changes the RTP in 19%. PET can aid in anal cancer staging and identification of residual disease, recurrent/metastatic disease but warrants further prospective studies.
Gov't Doc #: 18453023
DOI: 10.1016/j.radonc.2008.04.003
Type: Journal Article
Subjects: Adult
Aged, 80 and over
Anus Neoplasms.radionuclide imaging.radiotherapy
Carcinoma, Squamous Cell.radionuclide imaging.radiotherapy.secondary
Fluorodeoxyglucose F18.diagnostic use
Lymphatic Metastasis
Middle Aged
Positron-Emission Tomography
Radiopharmaceuticals.diagnostic use
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 1, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.